References
1. Agarwal S.K., et al. Application of the estrogen threshold hypothesis to the physiologic hypoestrogenemia of lactation. Breastfeed Med. 2015; 10 (2): 77-83.
2. Al-Ghazzewi F.H., Tester R.F. Biotherapeutic agents and vaginal health. J Appl Microbiol. 2016; 121 (1): 18-27.
3. Amabebe E., et al. Microbial dysbiosis-induced obesity: role of gut microbiota in ho-moeostasis of energy metabolism. Br J Nutr. 2020; 123 (10): 1127-37.
4. Amabebe E., Anumba D.O.C. The vaginal microenvironment: the physiologic role of Lactobacilli. Front Med. 2018; 5: 181.
5. Amabebe E., Anumba D.O.C. Female gut and genital tract microbiota-induced crosstalk and differential effects of short-chain fatty acids on immune sequelae. Front Immunol. 2020; 11: 2184.
6. Anukam K.C., et al. Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect. 2006; 8 (12-13): 2772-6.
7. Anukam K.C., et al. Yogurt containing probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 helps resolve moderate diarrhea and increases CD4 count in HIV/AIDS patients. J Clin Gastroenterol. 2008; 42 (3): 239-43.
8. Anukam K.C., et al. Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 may help downregulate TNF-alpha, IL-6, IL-8, IL-10 and IL-12 (p70) in the neurogenic bladder of spinal cord injured patient with urinary tract infections: a two-case study. Adv Urol. 2009; 2009: 680363.
9. Barthow C., et al. The Probiotics in Pregnancy Study (PiP Study): rationale and design of a double-blind randomised controlled trial to improve maternal health during pregnancy and prevent infant eczema and allergy. BMC Pregnancy Childb. 2016; 16 (1): 133.
10. Beerepoot M.A.J., et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med. 2012; 172 (9): 704-12.
11. Belkaid Y., Hand T.W. Role of the microbiota in immunity and inflammation. Cell. 2014; 157 (1): 121-41.
12. Biagi E., et al. Ageing of the human metaorganism: the microbial counterpart. Age. 2012; 34 (1): 247-67.
13. Bliss E.S., Whiteside E. The gut-brain axis, the human gut microbiota and their integration in the development of obesity. Front Physiol. 2018; 9: 900.
14. Bohbot J.M., Cardot J.M. Vaginal impact of the oral administration of total freeze-dried culture of LCR 35 in healthy women. Infect Dis Obstet Gynecol. 2012; 2012: 503648.
15. Boulange C.L., et al. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 2016; 8 (1): 42.
16. Brocklehurst P., et al. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013; 1: CD000262.
17. Brotman R.M., et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2018; 25 (11): 1321-30.
18. Brusselaers N., et al. Vaginal dysbiosis and the risk of human papillomavirus and cervical cancer: systematic review and meta-analysis. Am J Obstet Gynecol. 2019; 221 (1): 9-18.e8.
19. Carda-Dieguez M., et al. Variations in vaginal, penile, and oral microbiota after sexual intercourse: a case report. Front Med. 2019; 6: 178.
20. Castelo-Branco C., et al. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas. 2005; 52 (suppl 1): S46-52.
21. Cerdo T., et al. Probiotic, prebiotic, and brain development. Nutrients. 2017; 9 (11): 1247.
22. Chee W.J.Y., Chew S.Y., Than L.T.L. Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health. Microb Cell Fact. 2020; 19 (1): 203.
23. Cheng Y., Ling Z., Li L. The intestinal microbiota and colorectal cancer. Front Immunol. 2020; 11: 615056.
24. Cho C.E., Norman M. Cesarean section and development of the immune system in the offspring. Am J Obstet Gynecol. 2013; 208 (4): 249-54.
25. Clarke G., et al. Minireview: gut microbiota: the neglected endocrine organ. Mol Endocrinol. 2014; 28 (8): 1221-38.
26. Cribby S., Taylor M., Reid G. Vaginal microbiota and the use of probiotics. Interdiscip Perspect Infect Dis. 2008; 2008: 256490.
27. Ding H.T., Taur Y., Walkup J.T. Gut microbiota and autism: key concepts and findings. J Autism Dev Disord. 2017; 47 (2): 480-489.
28. Dominguez-Bello M.G., et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci USA. 2010; 107 (26): 11 971-5.
29. Dominguez-Bello M.G., et al. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer. Nat Med. 2016; 22 (3): 250-3.
30. Donders G.G., Zodzika J., Rezeberga D. Treatment of bacterial vaginosis: what we have and what we miss. Expert Opin Pharmacother. 2014; 15 (5): 645-57.
31. Evans J.M., Morris L.S., Marchesi J.R. The gut microbiome: the role of a virtual organ in the endocrinology of the host. J Endocrinol. 2013; 218 (3): R37-47.
32. FAO and WHO Working Group Guidelines for the evaluation of probiotics in food. In: Guidelines for the Evaluation of Probiotics in Food. 2002.
33. FDA GRAS Notice 845 for Lactobacillus rhamnosus LGG. FDA, 2019: 83.
34. Franasiak J.M., Scott R.T. Reproductive tract microbiome in assisted reproductive technologies. Fertil Steril. 2015; 104 (6): 1364-71.
35. Gagliardi A., et al. Rebuilding the gut microbiota ecosystem. Int J Environ Res Public Health. 2018; 15 (8): 1679.
36. Gibson G.R., et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017; 14 (8): 491-502.
37. Gueimonde M., et al. Effect of maternal consumption of Lactobacillus GG on transfer and establishment of fecal bifidobacterial microbiota in neonates. J Pediatr Gastroenterol Nutr. 2006; 42 (2): 166-170.
38. Gurung M., et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020; 51: 102590.
39. Harper A., et al. Viral infections, the microbiome, and probiotics. Front Cell Infect Microbiol. 2021; 10: 596166.
40. Ho M., et al. Oral Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 to reduce Group B Streptococcus colonization in pregnant women: a randomized controlled trial. Taiwan J Obstet Gynecol. 2016; 55 (4): 515-8.
41. Holmes E., et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature. 2008; 453 (7193): 396-400.
42. Holscher H.D. Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes. 2017; 8 (2): 172-84.
43. Huang H., Song L., Zhao W. Effects of probiotics for the treatment of bacterial vaginosis in adult women: a meta-analysis of randomized clinical trials. Arch Gynecol Obstet. 2014; 289 (6): 1225-34.
44. Jazani N., et al. Impact of gut dysbiosis on neurohormonal pathways in chronic kidney disease. Diseases. 2019; 7 (1): 21.
45. Kalliomaki M., et al. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007; 119 (4): 1019-21.
46. Kang H.J., Im S.H. Probiotics as an immune modulator. J Nutr Sci Vitaminol. 2015; 61: S103-5.
47. Kaur H., et al. Crosstalk between female gonadal hormones and vaginal microbiota across various phases of women's gynecological lifecycle. Front Microbiol. 2020; 11: 551.
48. Khanna S., Raffals L.E. The microbiome in Crohn's disease: role in pathogenesis and role of microbiome replacement therapies. Gastroenterol Clin North Am. 2017; 46 (3): 481-92.
49. Krauss-Silva L., et al. A randomised controlled trial of probiotics for the prevention of spontaneous preterm delivery associated with bacterial vaginosis: preliminary results. Trials. 2011; 12: 239.
50. Kukkonen K., et al. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics. 2008; 122 (1): 8-12.
51. Lazar V., et al. Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. Front Immunol. 2018; 9: 1830.
52. Ledingham K., Hinchliffe S., Jackson M. Cultural contexts of health and well-being. Antibiotic resistance: integrating cultural contexts of health in addressing the global health problem. WHO, 2019: 84 p
53. Othman M., Neilson J.P., Alfirevic Z. Probiotics for preventing preterm labour. Cochrane Database Syst Rev. 2007; 1: CD005941.
54. Makki K., et al. The impact of dietary fiber on gut microbiota in host health and disease. Cell Host Microbe. 2018; 23 (6): 705-15.
55. Maldonado Galdeano C., et al. Beneficial effects of probiotic consumption on the immune system. Ann Nutr Metab. 2019; 74 (2): 115-24.
56. Marchesi J.R., Ravel J. The vocabulary of microbiome research: a proposal. Micro-biome. 2015; 3 (1): 31.
57. Martinez R.C.R., et al. Improved cure of bacterial vaginosis with single dose of tini-dazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double-blind, placebo-controlled trial. Can J Microbiol. 2009; 55 (2): 133-8.
58. Martinez R.C.R., et al. Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14. Lett Appl Microbiol. 2009; 48 (3): 269-74.
59. Marziali G., et al. In-vitro effect of vaginal lactobacilli against group B Streptococcus. Microb Pathog. 2019; 136: 103692.
60. Mezzasalma V., et al. Orally administered multispecies probiotic formulations to prevent uro-genital infections: a randomized placebo-controlled pilot study. Arch Gynecol Obstet. 2017; 295 (1): 163-72.
61. Morelli L., et al. Utilization of the intestinal tract as a delivery system for urogenital probiotics. J Clin Gastroenterol. 2004; 38 (6): S107-10.
62. Moscicki A.B., et al. Cervical-vaginal microbiome and associated cytokine profiles in a prospective study of HPV 16 acquisition, persistence, and clearance. Front Cell Infect Microbiol. 2020; 10: 569022.
63. Nappi R.E., Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) -results from an international survey. Climacteric. 2012; 15 (1): 36-44.
64. Needell J.C., Zipris D. The role of the intestinal microbiome in type 1 diabetes pathogenesis. Curr Diabetes Rep. 2016; 16 (10): 89.
65. Noyes N., et al. Associations between sexual habits, menstrual hygiene practices, demographics and the vaginal microbiome as revealed by Bayesian network analysis. PLoS One. 2018; 13 (1): e0191625.
66. Palacios S. Managing urogenital atrophy. Maturitas. 2009; 63 (4): 315-8.
67. Parma M., et al. The role of vaginal Lactobacillus Rhamnosus (Normogin®) in preventing bacterial vaginosis in women with history of recurrences, undergoing surgical menopause: a prospective pilot study. Eur Rev Med Pharmacol Sci. 2013; 17 (10): 1399-403.
68. Perez-Brocal V., Latorre A., Moya A. Symbionts and pathogens: what is the difference? Curr Top Microbiol Immunol. 2013; 358: 215-43.
69. Petricevic L., et al. Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 2008; 141 (1): 54-7.
70. Quaranta G., Sanguinetti M., Masucci L. Fecal microbiota transplantation: a potential tool for treatment of human female reproductive tract diseases. Front Immunol. 2019; 10: 2653.
71. Reid G., et al. Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. FEMS Immunol Med Microbiol. 2001; 32 (1): 37-41.
72. Reid G., et al. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol. 2003; 35 (2): 131-4.
73. Reid G. Cervicovaginal microbiomes-threats and possibilities. Trends Endocrinol Metab. 2016; 27 (7): 446-54.
74. Riviere A., et al. Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front Microbiol. 2016; 7: 979.
75. Rosenberg E., DeLong E.F., Thompson F., Lory S., Stackebrandt E., et al. The Prokaryotes: Human Microbiology. In: E. Rosenberg et al. (eds). Berlin; Heidelberg: Springer-Verlag, 2013: 554 p.
76. Sanders M.E., et al. Safety assessment of probiotics for human use. Gut Microbes. 2010; 1 (3): 164-85.
77. Sherman D., et al. Characteristics of normal lochia. Am J Perinatol. 1999; 16 (8): 399-402.
78. Staude B., et al. The microbiome and preterm birth: a change in paradigm with profound implications for pathophysiologic concepts and novel therapeutic strategies. Biomed Res Int. 2018; 2018: 7218187.
79. Tachedjian G., et al. The role of lactic acid production by probiotic Lactobacillus species in vaginal health. Res Microbiol. 2017; 168 (9-10): 782-92.
80. Tester R., Al-Ghazzewi F.H. Intrinsic and extrinsic carbohydrates in the vagina: a short review on vaginal glycogen. Int J Biol Macromol. 2018; 112: 203-6.
81. Thursby E., Juge N. Introduction to the human gut microbiota. Biochem J. 2017; 474 (11): 1823-36.
82. Ursell L.K., et al. Defining the human microbiome. Nutr Rev. 2012; 70 (1): S38.